Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) kicked off on Friday, down -1.47% from the previous trading day, before settling in for the closing price of $15.67. Over the past 52 weeks, RDY has traded in a range of $13.43-$16.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 8.97%. While this was happening, its average annual earnings per share was recorded 1.83%. With a float of $833.03 million, this company’s outstanding shares have now reached $834.38 million.
The extent of productivity of a business whose workforce counts for 27048 workers is very important to gauge. In terms of profitability, gross margin is 59.29%, operating margin of 22.52%, and the pretax margin is 24.1%.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Dr. Reddy’s Laboratories Ltd. ADR is 0.00%, while institutional ownership is 14.48%. The most recent insider transaction that took place on Jul 29 ’24, was worth 5,390,000.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 16.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.74% during the next five years compared to 20.07% growth over the previous five years of trading.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) Trading Performance Indicators
Take a look at Dr. Reddy’s Laboratories Ltd. ADR’s (RDY) current performance indicators. Last quarter, stock had a quick ratio of 1.36. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.58. Likewise, its price to free cash flow for the trailing twelve months is 93.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.77, a number that is poised to hit 0.22 in the next quarter and is forecasted to reach 0.81 in one year’s time.
Technical Analysis of Dr. Reddy’s Laboratories Ltd. ADR (RDY)
The latest stats from [Dr. Reddy’s Laboratories Ltd. ADR, RDY] show that its last 5-days average volume of 1.5 million was inferior to 1.52 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 52.93%. Additionally, its Average True Range was 0.27.
During the past 100 days, Dr. Reddy’s Laboratories Ltd. ADR’s (RDY) raw stochastic average was set at 51.87%, which indicates a significant decrease from 62.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 22.48% in the past 14 days, which was higher than the 20.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.80, while its 200-day Moving Average is $15.14. Now, the first resistance to watch is $15.51. This is followed by the second major resistance level at $15.57. The third major resistance level sits at $15.62. If the price goes on to break the first support level at $15.40, it is likely to go to the next support level at $15.35. The third support level lies at $15.29 if the price breaches the second support level.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) Key Stats
The company with the Market Capitalisation of 12.86 billion has total of 834,727K Shares Outstanding. Its annual sales at the moment are 3,350 M in contrast with the sum of 668,000 K annual income. Company’s last quarter sales were recorded 953,930 K and last quarter income was 149,380 K.
